View Future GrowthThis company listing is no longer activeThis company may still be operating, however this listing is no longer active. Find out why through their latest events.See Latest EventsLannett Company 과거 순이익 실적과거 기준 점검 0/6Lannett Company 의 수입은 연평균 -21.9%의 비율로 감소해 온 반면, Pharmaceuticals 산업은 연평균 9.4%의 비율로 증가했습니다. 매출은 연평균 16.4%의 비율로 감소해 왔습니다.핵심 정보-21.88%순이익 성장률-20.03%주당순이익(EPS) 성장률Pharmaceuticals 산업 성장률5.95%매출 성장률-16.40%자기자본이익률n/a순이익률-83.40%최근 순이익 업데이트31 Mar 2023최근 과거 실적 업데이트Reported Earnings • Feb 03Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2023 results: US$0.88 loss per share (improved from US$2.01 loss in 2Q 2022). Revenue: US$80.9m (down 6.5% from 2Q 2022). Net loss: US$36.3m (loss narrowed 55% from 2Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 110%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.공시 • Feb 02+ 1 more updateLannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022Lannett Company, Inc. reported asset impairment for the second quarter ended December 31, 2022. For the quarter, the company reported asset impairment charges of $5,969,000 against $49,361,000 a year ago.공시 • Jan 26Lannett Company, Inc. to Report Q2, 2023 Results on Feb 01, 2023Lannett Company, Inc. announced that they will report Q2, 2023 results After-Market on Feb 01, 2023Reported Earnings • Nov 04First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2023 results: US$0.68 loss per share (further deteriorated from US$0.56 loss in 1Q 2022). Revenue: US$75.1m (down 26% from 1Q 2022). Net loss: US$28.0m (loss widened 25% from 1Q 2022). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 51%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 2 percentage points per year.Reported Earnings • Aug 25Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$5.74 loss per share (up from US$9.23 loss in FY 2021). Revenue: US$340.6m (down 29% from FY 2021). Net loss: US$231.6m (loss narrowed 36% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 230%. Over the next year, revenue is forecast to grow 1.0%, compared to a 25% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.Reported Earnings • May 06Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.86 loss per share (down from US$0.18 loss in 3Q 2021). Revenue: US$78.4m (down 30% from 3Q 2021). Net loss: US$34.9m (loss widened 389% from 3Q 2021). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) also missed analyst estimates by 110%. Over the next year, revenue is expected to shrink by 7.1% compared to a 7.6% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 57% per year, which means it is performing significantly worse than earnings.모든 업데이트 보기Recent updates공시 • Jun 21Lannett Company, Inc. Files Form 15Lannett Company, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001per share.Reported Earnings • Feb 03Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2023 results: US$0.88 loss per share (improved from US$2.01 loss in 2Q 2022). Revenue: US$80.9m (down 6.5% from 2Q 2022). Net loss: US$36.3m (loss narrowed 55% from 2Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 110%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.공시 • Feb 02+ 1 more updateLannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022Lannett Company, Inc. reported asset impairment for the second quarter ended December 31, 2022. For the quarter, the company reported asset impairment charges of $5,969,000 against $49,361,000 a year ago.공시 • Jan 26Lannett Company, Inc. to Report Q2, 2023 Results on Feb 01, 2023Lannett Company, Inc. announced that they will report Q2, 2023 results After-Market on Feb 01, 2023Seeking Alpha • Jan 25Lannett announces 1-for-4 reverse stock splitLannett (NYSE:LCI) said its board approved a 1-for-4 reverse stock split of its issued and outstanding shares, which will be effective at 5 p.m. Eastern Time on February 6. No fractional shares will be issued in connection with the reverse stock split, the company said.공시 • Jan 05Lannett Company Provides Development Update on Biosimilar Insulin ProductsOn January 4, 2023, Lannett Company, Inc. provided an update on the clinical advancement and development of its biosimilar insulin aspart and biosimilar insulin glargine products. Lannett is developing both products with its strategic alliance partner, the HEC Group of companies (HEC). The company said results from the study of Lannett/HEC biosimilar insulin aspart versus US NovoLog® (the reference biologic) indicated the products were highly comparable when animals were dosed with equal quantities of the drugs via subcutaneous route. Data from the study will be submitted to the FDA as part of the company's request, expected in the first half of calendar 2023, for a Biosimilar Biological Product Development (BPD) Type II meeting. The company also said that analysis of the pivotal trial results for its biosimilar insulin glargine continues, though it now anticipates top-line data to be available by the end of February 2023.공시 • Nov 30Lannett Company, Inc., Annual General Meeting, Jan 25, 2023Lannett Company, Inc., Annual General Meeting, Jan 25, 2023, at 09:00 US Eastern Standard Time. Location: 1150 Northbrook Drive Trevose, PA 19053 Trevose Pennsylvania United States Agenda: To elect five (5) members of the board of directors (the “board”) to serve until the next annual meeting of stockholders; to ratify the selection of grant thornton, llp as independent auditors for the fiscal year ending june 30, 2023; to obtain a non-binding advisory vote on the compensation of the company’s executive officers; to approve a proposed amendment to Certificate of Incorporation (the “Certificate of Incorporation”); to approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve the Reverse Stock Split proposal at the time of the Annual Meeting or in the absence of a quorum; and to transact such other business as may properly come before the annual meeting or any adjournment thereof.Price Target Changed • Nov 16Price target decreased to US$1.00Down from US$2.25, the current price target is provided by 1 analyst. New target price is 96% above last closing price of US$0.51. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$1.47 next year compared to a net loss per share of US$5.74 last year.Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Melissa Rewolinski was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Seeking Alpha • Nov 07Lannett gains on patent deal for biosimilar insulin deviceThe shares of generic drugmaker Lannett Company (NYSE:LCI) added ~9% on Monday after announcing a licensing deal for patents related to a pen injector device for its investigational biosimilar products, insulin glargine and insulin aspart. Per the terms, Lannett (LCI) and its partner HEC Group of companies will sublicense to a licensing arrangement between Ypsomed AG, the maker of the device, and Sanofi (SNY) unit Sanofi-Aventis Deutschland GmbH, which owns several patents related to the device. The financial details of the deal were not disclosed. "In short, we have significantly improved our ability to freely market our biosimilar insulin products, once approved," Lannett (LCI) Chief Executive Tim Crew remarked. The company plans to submit a marketing application for biosimilar and interchangeable insulin glargine targeting Sanofi's (SNY) Lantus in 2023 spring, expecting a potential launch in H1 2024. Last week, Lannett (LCI) exceeded Street forecasts with its Q1 financials for fiscal 2023.Reported Earnings • Nov 04First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2023 results: US$0.68 loss per share (further deteriorated from US$0.56 loss in 1Q 2022). Revenue: US$75.1m (down 26% from 1Q 2022). Net loss: US$28.0m (loss widened 25% from 1Q 2022). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 51%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 2 percentage points per year.Seeking Alpha • Oct 21Lannett gets FDA approval to manufacture Numbrino® at Seymour plantThe U.S. Food and Drug Administration (FDA) approved micro-cap generic drugmaker Lannett Company (NYSE:LCI) to rapidly expand liquid drug manufacturing of Numbrino®, the company's branded topical anesthetic product, at its main plant in Seymour, Indiana. The company previously manufactured Numbrino and other liquid drug products at its Carmel, New York plant, which it sold in March of this year as part of a restructuring and cost reduction plan. NUMBRINO is indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.Major Estimate Revision • Sep 01Consensus revenue estimates fall by 16%The consensus outlook for revenues in 2023 has deteriorated. 2023 revenue forecast decreased from US$344.0m to US$288.9m. Forecast losses increased from -US$1.39 to -US$1.54 per share. Pharmaceuticals industry in the US expected to see average net income growth of 0.1% next year. Consensus price target down from US$2.25 to US$1.00. Share price fell 14% to US$0.49 over the past week.분석 기사 • Sep 01Lannett Company, Inc. (NYSE:LCI) Analysts Just Slashed This Year's EstimatesToday is shaping up negative for Lannett Company, Inc. ( NYSE:LCI ) shareholders, with the analysts delivering a...Reported Earnings • Aug 25Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$5.74 loss per share (up from US$9.23 loss in FY 2021). Revenue: US$340.6m (down 29% from FY 2021). Net loss: US$231.6m (loss narrowed 36% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 230%. Over the next year, revenue is forecast to grow 1.0%, compared to a 25% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.Seeking Alpha • Aug 24Lannett GAAP EPS of -$2.30, revenue of $74.19MLannett press release (NYSE:LCI): Q4 GAAP EPS of -$2.30; Non-GAAP EPS of -$0.44 Revenue of $74.19M (-30.0% Y/Y). Adjusted gross profit was $10.4 million, or 14% of net sales, compared with $26.4 million, or 25% of net sales. Negative adjusted EBITDA was $1.3 million versus adjusted EBITDA of $12.1 million. FY 2023 Guidance: Revenue expected between $275 million to $300 million; Adjusted Gross margin of approximately 15% to 17%; and Capex of approximately $8 million to $12 million.Board Change • Aug 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Melissa Rewolinski was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.Reported Earnings • May 06Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.86 loss per share (down from US$0.18 loss in 3Q 2021). Revenue: US$78.4m (down 30% from 3Q 2021). Net loss: US$34.9m (loss widened 389% from 3Q 2021). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) also missed analyst estimates by 110%. Over the next year, revenue is expected to shrink by 7.1% compared to a 7.6% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 57% per year, which means it is performing significantly worse than earnings.Price Target Changed • Apr 27Price target decreased to US$3.00Down from US$5.00, the current price target is an average from 2 analysts. New target price is 414% above last closing price of US$0.58. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$1.74 next year compared to a net loss per share of US$9.23 last year.Seeking Alpha • Feb 22Lannett: A Self-Inflicted CrisisLannett finds itself at a confluence of choices brought forth more by management than the macro-environment. With revenues sinking to new lows, investors are left wondering if management can find a path to the aspirational goal of $1 billion in revenues by 2025. With a share price lower than the threshold necessary for listing on the NYSE, down from a record high in 2015 of $72.44, investors must wonder what happened to Lannett.분석 기사 • Feb 05Analysts Just Made A Major Revision To Their Lannett Company, Inc. (NYSE:LCI) Revenue ForecastsOne thing we could say about the analysts on Lannett Company, Inc. ( NYSE:LCI ) - they aren't optimistic, having just...Reported Earnings • Feb 05Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: US$2.01 loss per share (up from US$4.36 loss in 2Q 2021). Revenue: US$86.5m (down 35% from 2Q 2021). Net loss: US$81.1m (loss narrowed 53% from 2Q 2021). Revenue missed analyst estimates by 4.1%. Earnings per share (EPS) exceeded analyst estimates by 474%. Over the next year, revenue is expected to shrink by 1.1% compared to a 19% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.Recent Insider Transactions • Dec 04Non-Executive Independent Chairman recently bought US$86k worth of stockOn the 29th of November, Patrick LePore bought around 50k shares on-market at roughly US$1.71 per share. This was the largest purchase by an insider in the last 3 months. Patrick has been a buyer over the last 12 months, purchasing a net total of US$235k worth in shares.Reported Earnings • Nov 05First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.17 loss in 1Q 2021)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2022 results: Revenue: US$101.5m (down 20% from 1Q 2021). Net loss: US$22.3m (loss widened 244% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.분석 기사 • Nov 05A Look At The Fair Value Of Lannett Company, Inc. (NYSE:LCI)How far off is Lannett Company, Inc. ( NYSE:LCI ) from its intrinsic value? Using the most recent financial data, we'll...Price Target Changed • Nov 05Price target decreased to US$5.00Down from US$6.00, the current price target is an average from 2 analysts. New target price is 116% above last closing price of US$2.32. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$1.32 next year compared to a net loss per share of US$9.23 last year.Recent Insider Transactions • Sep 14Independent Director recently sold US$81k worth of stockOn the 9th of September, Melissa Rewolinski sold around 25k shares on-market at roughly US$3.18 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$90k more than they bought in the last 12 months.Recent Insider Transactions Derivative • Sep 13Independent Director notifies of intention to sell stockMelissa Rewolinski intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of September. If the sale is conducted around the recent share price of US$3.18, it would amount to US$81k. Since December 2020, Melissa's direct individual holding has increased from 44.77k shares to 87.44k. Company insiders have collectively sold US$9.8k more than they bought, via options and on-market transactions in the last 12 months.Reported Earnings • Aug 27Full year 2021 earnings released: US$9.23 loss per share (vs US$0.86 loss in FY 2020)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: US$478.8m (down 12% from FY 2020). Net loss: US$363.5m (loss widened US$330.1m from FY 2020). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.Price Target Changed • Aug 26Price target increased to US$7.00Up from US$5.88, the current price target is an average from 3 analysts. New target price is 86% above last closing price of US$3.77. Stock is down 27% over the past year.Board Change • Aug 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Melissa Rewolinski was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.분석 기사 • Jun 20Is Lannett Company (NYSE:LCI) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...Recent Insider Transactions • May 14Non-Executive Independent Chairman recently bought US$84k worth of stockOn the 11th of May, Patrick LePore bought around 20k shares on-market at roughly US$4.18 per share. This was the largest purchase by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months.Price Target Changed • May 12Price target decreased to US$5.88Down from US$6.38, the current price target is an average from 5 analysts. New target price is 41% above last closing price of US$4.17. Stock is down 44% over the past year.Reported Earnings • May 07Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.43 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$112.4m (down 22% from 3Q 2020). Net loss: US$7.14m (loss narrowed 57% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.분석 기사 • Mar 18Is Lannett Company (NYSE:LCI) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...Is New 90 Day High Low • Feb 24New 90-day low: US$5.93The company is down 6.0% from its price of US$6.28 on 25 November 2020. The American market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$25.11 per share.Recent Insider Transactions • Feb 11Independent Director recently sold US$203k worth of stockOn the 8th of February, David Drabik sold around 33k shares on-market at roughly US$6.08 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$700k more than they bought in the last 12 months.분석 기사 • Feb 11Independent Director David Drabik Just Sold A Bunch Of Shares In Lannett Company, Inc. (NYSE:LCI)We'd be surprised if Lannett Company, Inc. ( NYSE:LCI ) shareholders haven't noticed that the Independent Director...Reported Earnings • Feb 05Second quarter 2021 earnings released: US$4.36 loss per share (vs US$0.13 profit in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: US$133.9m (down 1.6% from 2Q 2020). Net loss: US$171.9m (down US$177.0m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.Analyst Estimate Surprise Post Earnings • Feb 05Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 8,620%. Over the next year, revenue is forecast to grow 1.1%, compared to a 31% growth forecast for the Pharmaceuticals industry in the US.Is New 90 Day High Low • Jan 26New 90-day high: US$7.93The company is up 19% from its price of US$6.67 on 27 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$33.65 per share.분석 기사 • Jan 15What Type Of Returns Would Lannett Company's(NYSE:LCI) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...분석 기사 • Dec 11Is Lannett Company (NYSE:LCI) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Reported Earnings • Nov 06First quarter 2021 earnings released: US$0.17 loss per shareThe company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were flat. First quarter 2021 results: Revenue: US$126.5m (flat on 1Q 2020). Net loss: US$6.50m (loss narrowed 47% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.Analyst Estimate Surprise Post Earnings • Nov 06Revenue and earnings miss expectationsRevenue missed analyst estimates by 1.9%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to stay flat compared to a 31% growth forecast for the Pharmaceuticals industry in the US.Price Target Changed • Oct 15Price target lowered to US$7.75Down from US$9.75, the current price target is an average from 5 analysts. The new target price is 16% above the current share price of US$6.66. As of last close, the stock is down 44% over the past year.매출 및 비용 세부 내역Lannett Company가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.순이익 및 매출 추이OTCPK:LCIN.Q 매출, 비용 및 순이익 (USD Millions)날짜매출순이익일반관리비연구개발비31 Mar 23311-259812531 Dec 22309-193782430 Sep 22314-237792430 Jun 22341-232812231 Mar 22372-316772231 Dec 21406-288772330 Sep 21454-379722330 Jun 21479-363682431 Mar 21511-195652531 Dec 20543-205702630 Sep 20545-28732830 Jun 20546-33793031 Mar 20542-31833331 Dec 19570-4833530 Sep 196283883830 Jun 19655-272883931 Mar 19692-276813831 Dec 18694-274733130 Sep 18685-272793230 Jun 1868529822931 Mar 1865346783231 Dec 1764448823830 Sep 1763142713730 Jun 17637-1734231 Mar 17667-3794431 Dec 16665-23775230 Sep 16621-18745130 Jun 1656645684531 Mar 1649675593931 Dec 15432117543230 Sep 15420148503130 Jun 15407150453031 Mar 15388140453031 Dec 14369126433130 Sep 1432198422930 Jun 1427457392831 Mar 1423337322531 Dec 1319218281930 Sep 131624231730 Jun 1315113221631 Mar 1314711221731 Dec 121389221430 Sep 121297221330 Jun 1212342012양질의 수익: LCIN.Q 은(는) 현재 수익성이 없습니다.이익 마진 증가: LCIN.Q는 현재 수익성이 없습니다.잉여현금흐름 대비 순이익 분석과거 순이익 성장 분석수익추이: LCIN.Q은 수익성이 없으며 지난 5년 동안 손실이 연평균 21.9% 증가했습니다.성장 가속화: 현재 수익성이 없어 지난 1년간 LCIN.Q의 수익 성장률을 5년 평균과 비교할 수 없습니다.수익 대 산업: LCIN.Q은 수익성이 없어 지난 해 수익 성장률을 Pharmaceuticals 업계(-4.8%)와 비교하기 어렵습니다.자기자본이익률높은 ROE: LCIN.Q의 부채가 자산을 초과하여 자본 수익률을 계산하기 어렵습니다.총자산이익률투하자본수익률우수한 과거 실적 기업을 찾아보세요7D1Y7D1Y7D1YPharmaceuticals-biotech 산업에서 과거 실적이 우수한 기업.View Financial Health기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2023/06/21 18:44종가2023/06/16 00:00수익2023/03/31연간 수익2022/06/30데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Lannett Company, Inc.는 11명의 분석가가 다루고 있습니다. 이 중 명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.분석가기관Gary NachmanBMO Capital Markets Equity ResearchSumant Satchidanand KulkarniBofA Global ResearchJohn NewmanCanaccord Genuity8명의 분석가 더 보기
Reported Earnings • Feb 03Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2023 results: US$0.88 loss per share (improved from US$2.01 loss in 2Q 2022). Revenue: US$80.9m (down 6.5% from 2Q 2022). Net loss: US$36.3m (loss narrowed 55% from 2Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 110%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.
공시 • Feb 02+ 1 more updateLannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022Lannett Company, Inc. reported asset impairment for the second quarter ended December 31, 2022. For the quarter, the company reported asset impairment charges of $5,969,000 against $49,361,000 a year ago.
공시 • Jan 26Lannett Company, Inc. to Report Q2, 2023 Results on Feb 01, 2023Lannett Company, Inc. announced that they will report Q2, 2023 results After-Market on Feb 01, 2023
Reported Earnings • Nov 04First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2023 results: US$0.68 loss per share (further deteriorated from US$0.56 loss in 1Q 2022). Revenue: US$75.1m (down 26% from 1Q 2022). Net loss: US$28.0m (loss widened 25% from 1Q 2022). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 51%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 2 percentage points per year.
Reported Earnings • Aug 25Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$5.74 loss per share (up from US$9.23 loss in FY 2021). Revenue: US$340.6m (down 29% from FY 2021). Net loss: US$231.6m (loss narrowed 36% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 230%. Over the next year, revenue is forecast to grow 1.0%, compared to a 25% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
Reported Earnings • May 06Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.86 loss per share (down from US$0.18 loss in 3Q 2021). Revenue: US$78.4m (down 30% from 3Q 2021). Net loss: US$34.9m (loss widened 389% from 3Q 2021). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) also missed analyst estimates by 110%. Over the next year, revenue is expected to shrink by 7.1% compared to a 7.6% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 57% per year, which means it is performing significantly worse than earnings.
공시 • Jun 21Lannett Company, Inc. Files Form 15Lannett Company, Inc. has announced that it has filed a Form 15 with the Securities and Exchange Commission to voluntarily deregister its Common Stock under the Securities Exchange Act of 1934, as amended. The par value of the company's Common Stock was $0.001per share.
Reported Earnings • Feb 03Second quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindSecond quarter 2023 results: US$0.88 loss per share (improved from US$2.01 loss in 2Q 2022). Revenue: US$80.9m (down 6.5% from 2Q 2022). Net loss: US$36.3m (loss narrowed 55% from 2Q 2022). Revenue exceeded analyst estimates by 11%. Earnings per share (EPS) missed analyst estimates by 110%. Revenue is forecast to grow 6.1% p.a. on average during the next 3 years, compared to a 4.5% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 46% per year but the company’s share price has fallen by 58% per year, which means it is performing significantly worse than earnings.
공시 • Feb 02+ 1 more updateLannett Company, Inc. Reports Asset Impairment for the Second Quarter Ended December 31, 2022Lannett Company, Inc. reported asset impairment for the second quarter ended December 31, 2022. For the quarter, the company reported asset impairment charges of $5,969,000 against $49,361,000 a year ago.
공시 • Jan 26Lannett Company, Inc. to Report Q2, 2023 Results on Feb 01, 2023Lannett Company, Inc. announced that they will report Q2, 2023 results After-Market on Feb 01, 2023
Seeking Alpha • Jan 25Lannett announces 1-for-4 reverse stock splitLannett (NYSE:LCI) said its board approved a 1-for-4 reverse stock split of its issued and outstanding shares, which will be effective at 5 p.m. Eastern Time on February 6. No fractional shares will be issued in connection with the reverse stock split, the company said.
공시 • Jan 05Lannett Company Provides Development Update on Biosimilar Insulin ProductsOn January 4, 2023, Lannett Company, Inc. provided an update on the clinical advancement and development of its biosimilar insulin aspart and biosimilar insulin glargine products. Lannett is developing both products with its strategic alliance partner, the HEC Group of companies (HEC). The company said results from the study of Lannett/HEC biosimilar insulin aspart versus US NovoLog® (the reference biologic) indicated the products were highly comparable when animals were dosed with equal quantities of the drugs via subcutaneous route. Data from the study will be submitted to the FDA as part of the company's request, expected in the first half of calendar 2023, for a Biosimilar Biological Product Development (BPD) Type II meeting. The company also said that analysis of the pivotal trial results for its biosimilar insulin glargine continues, though it now anticipates top-line data to be available by the end of February 2023.
공시 • Nov 30Lannett Company, Inc., Annual General Meeting, Jan 25, 2023Lannett Company, Inc., Annual General Meeting, Jan 25, 2023, at 09:00 US Eastern Standard Time. Location: 1150 Northbrook Drive Trevose, PA 19053 Trevose Pennsylvania United States Agenda: To elect five (5) members of the board of directors (the “board”) to serve until the next annual meeting of stockholders; to ratify the selection of grant thornton, llp as independent auditors for the fiscal year ending june 30, 2023; to obtain a non-binding advisory vote on the compensation of the company’s executive officers; to approve a proposed amendment to Certificate of Incorporation (the “Certificate of Incorporation”); to approve one or more adjournments of the Annual Meeting to a later date or dates if necessary or appropriate to solicit additional proxies if there are insufficient votes to approve the Reverse Stock Split proposal at the time of the Annual Meeting or in the absence of a quorum; and to transact such other business as may properly come before the annual meeting or any adjournment thereof.
Price Target Changed • Nov 16Price target decreased to US$1.00Down from US$2.25, the current price target is provided by 1 analyst. New target price is 96% above last closing price of US$0.51. Stock is down 74% over the past year. The company is forecast to post a net loss per share of US$1.47 next year compared to a net loss per share of US$5.74 last year.
Board Change • Nov 16Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Melissa Rewolinski was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Seeking Alpha • Nov 07Lannett gains on patent deal for biosimilar insulin deviceThe shares of generic drugmaker Lannett Company (NYSE:LCI) added ~9% on Monday after announcing a licensing deal for patents related to a pen injector device for its investigational biosimilar products, insulin glargine and insulin aspart. Per the terms, Lannett (LCI) and its partner HEC Group of companies will sublicense to a licensing arrangement between Ypsomed AG, the maker of the device, and Sanofi (SNY) unit Sanofi-Aventis Deutschland GmbH, which owns several patents related to the device. The financial details of the deal were not disclosed. "In short, we have significantly improved our ability to freely market our biosimilar insulin products, once approved," Lannett (LCI) Chief Executive Tim Crew remarked. The company plans to submit a marketing application for biosimilar and interchangeable insulin glargine targeting Sanofi's (SNY) Lantus in 2023 spring, expecting a potential launch in H1 2024. Last week, Lannett (LCI) exceeded Street forecasts with its Q1 financials for fiscal 2023.
Reported Earnings • Nov 04First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behindFirst quarter 2023 results: US$0.68 loss per share (further deteriorated from US$0.56 loss in 1Q 2022). Revenue: US$75.1m (down 26% from 1Q 2022). Net loss: US$28.0m (loss widened 25% from 1Q 2022). Revenue exceeded analyst estimates by 10%. Earnings per share (EPS) missed analyst estimates by 51%. Revenue is forecast to grow 5.2% p.a. on average during the next 3 years, compared to a 3.9% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, the company's share price growth rate has exceeded its earnings growth rate by 2 percentage points per year.
Seeking Alpha • Oct 21Lannett gets FDA approval to manufacture Numbrino® at Seymour plantThe U.S. Food and Drug Administration (FDA) approved micro-cap generic drugmaker Lannett Company (NYSE:LCI) to rapidly expand liquid drug manufacturing of Numbrino®, the company's branded topical anesthetic product, at its main plant in Seymour, Indiana. The company previously manufactured Numbrino and other liquid drug products at its Carmel, New York plant, which it sold in March of this year as part of a restructuring and cost reduction plan. NUMBRINO is indicated for the introduction of local anesthesia of the mucous membranes for diagnostic procedures and surgeries on or through the nasal cavities of adults.
Major Estimate Revision • Sep 01Consensus revenue estimates fall by 16%The consensus outlook for revenues in 2023 has deteriorated. 2023 revenue forecast decreased from US$344.0m to US$288.9m. Forecast losses increased from -US$1.39 to -US$1.54 per share. Pharmaceuticals industry in the US expected to see average net income growth of 0.1% next year. Consensus price target down from US$2.25 to US$1.00. Share price fell 14% to US$0.49 over the past week.
분석 기사 • Sep 01Lannett Company, Inc. (NYSE:LCI) Analysts Just Slashed This Year's EstimatesToday is shaping up negative for Lannett Company, Inc. ( NYSE:LCI ) shareholders, with the analysts delivering a...
Reported Earnings • Aug 25Full year 2022 earnings: EPS misses analyst expectationsFull year 2022 results: US$5.74 loss per share (up from US$9.23 loss in FY 2021). Revenue: US$340.6m (down 29% from FY 2021). Net loss: US$231.6m (loss narrowed 36% from FY 2021). Revenue was in line with analyst estimates. Earnings per share (EPS) missed analyst estimates by 230%. Over the next year, revenue is forecast to grow 1.0%, compared to a 25% growth forecast for the Pharmaceuticals industry in the US. Over the last 3 years on average, earnings per share has fallen by 51% per year but the company’s share price has fallen by 60% per year, which means it is performing significantly worse than earnings.
Seeking Alpha • Aug 24Lannett GAAP EPS of -$2.30, revenue of $74.19MLannett press release (NYSE:LCI): Q4 GAAP EPS of -$2.30; Non-GAAP EPS of -$0.44 Revenue of $74.19M (-30.0% Y/Y). Adjusted gross profit was $10.4 million, or 14% of net sales, compared with $26.4 million, or 25% of net sales. Negative adjusted EBITDA was $1.3 million versus adjusted EBITDA of $12.1 million. FY 2023 Guidance: Revenue expected between $275 million to $300 million; Adjusted Gross margin of approximately 15% to 17%; and Capex of approximately $8 million to $12 million.
Board Change • Aug 02Insufficient new directorsNo new directors have joined the board in the last 3 years. The company's board is composed of: No new directors. 4 experienced directors. 2 highly experienced directors. Independent Director Melissa Rewolinski was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
Reported Earnings • May 06Third quarter 2022 earnings: EPS and revenues miss analyst expectationsThird quarter 2022 results: US$0.86 loss per share (down from US$0.18 loss in 3Q 2021). Revenue: US$78.4m (down 30% from 3Q 2021). Net loss: US$34.9m (loss widened 389% from 3Q 2021). Revenue missed analyst estimates by 6.3%. Earnings per share (EPS) also missed analyst estimates by 110%. Over the next year, revenue is expected to shrink by 7.1% compared to a 7.6% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 38% per year but the company’s share price has fallen by 57% per year, which means it is performing significantly worse than earnings.
Price Target Changed • Apr 27Price target decreased to US$3.00Down from US$5.00, the current price target is an average from 2 analysts. New target price is 414% above last closing price of US$0.58. Stock is down 88% over the past year. The company is forecast to post a net loss per share of US$1.74 next year compared to a net loss per share of US$9.23 last year.
Seeking Alpha • Feb 22Lannett: A Self-Inflicted CrisisLannett finds itself at a confluence of choices brought forth more by management than the macro-environment. With revenues sinking to new lows, investors are left wondering if management can find a path to the aspirational goal of $1 billion in revenues by 2025. With a share price lower than the threshold necessary for listing on the NYSE, down from a record high in 2015 of $72.44, investors must wonder what happened to Lannett.
분석 기사 • Feb 05Analysts Just Made A Major Revision To Their Lannett Company, Inc. (NYSE:LCI) Revenue ForecastsOne thing we could say about the analysts on Lannett Company, Inc. ( NYSE:LCI ) - they aren't optimistic, having just...
Reported Earnings • Feb 05Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behindSecond quarter 2022 results: US$2.01 loss per share (up from US$4.36 loss in 2Q 2021). Revenue: US$86.5m (down 35% from 2Q 2021). Net loss: US$81.1m (loss narrowed 53% from 2Q 2021). Revenue missed analyst estimates by 4.1%. Earnings per share (EPS) exceeded analyst estimates by 474%. Over the next year, revenue is expected to shrink by 1.1% compared to a 19% growth forecast for the industry in the US. Over the last 3 years on average, earnings per share has fallen by 21% per year but the company’s share price has fallen by 52% per year, which means it is performing significantly worse than earnings.
Recent Insider Transactions • Dec 04Non-Executive Independent Chairman recently bought US$86k worth of stockOn the 29th of November, Patrick LePore bought around 50k shares on-market at roughly US$1.71 per share. This was the largest purchase by an insider in the last 3 months. Patrick has been a buyer over the last 12 months, purchasing a net total of US$235k worth in shares.
Reported Earnings • Nov 05First quarter 2022 earnings released: US$0.56 loss per share (vs US$0.17 loss in 1Q 2021)The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2022 results: Revenue: US$101.5m (down 20% from 1Q 2021). Net loss: US$22.3m (loss widened 244% from 1Q 2021). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 25% per year, which means it is performing significantly worse than earnings.
분석 기사 • Nov 05A Look At The Fair Value Of Lannett Company, Inc. (NYSE:LCI)How far off is Lannett Company, Inc. ( NYSE:LCI ) from its intrinsic value? Using the most recent financial data, we'll...
Price Target Changed • Nov 05Price target decreased to US$5.00Down from US$6.00, the current price target is an average from 2 analysts. New target price is 116% above last closing price of US$2.32. Stock is down 61% over the past year. The company is forecast to post a net loss per share of US$1.32 next year compared to a net loss per share of US$9.23 last year.
Recent Insider Transactions • Sep 14Independent Director recently sold US$81k worth of stockOn the 9th of September, Melissa Rewolinski sold around 25k shares on-market at roughly US$3.18 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$90k more than they bought in the last 12 months.
Recent Insider Transactions Derivative • Sep 13Independent Director notifies of intention to sell stockMelissa Rewolinski intends to sell 25k shares in the next 90 days after lodging an Intent To Sell Form on the 9th of September. If the sale is conducted around the recent share price of US$3.18, it would amount to US$81k. Since December 2020, Melissa's direct individual holding has increased from 44.77k shares to 87.44k. Company insiders have collectively sold US$9.8k more than they bought, via options and on-market transactions in the last 12 months.
Reported Earnings • Aug 27Full year 2021 earnings released: US$9.23 loss per share (vs US$0.86 loss in FY 2020)The company reported a poor full year result with increased losses, weaker revenues and weaker control over costs. Full year 2021 results: Revenue: US$478.8m (down 12% from FY 2020). Net loss: US$363.5m (loss widened US$330.1m from FY 2020). Over the last 3 years on average, earnings per share has fallen by 5% per year but the company’s share price has fallen by 11% per year, which means it is performing significantly worse than earnings.
Price Target Changed • Aug 26Price target increased to US$7.00Up from US$5.88, the current price target is an average from 3 analysts. New target price is 86% above last closing price of US$3.77. Stock is down 27% over the past year.
Board Change • Aug 02Insufficient new directorsThere is 1 new director who has joined the board in the last 3 years. The company's board is composed of: 1 new director. 3 experienced directors. 3 highly experienced directors. Independent Director Melissa Rewolinski was the last director to join the board, commencing their role in 2019. The company’s insufficient board refreshment is considered a risk according to the Simply Wall St Risk Model.
분석 기사 • Jun 20Is Lannett Company (NYSE:LCI) A Risky Investment?The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Recent Insider Transactions • May 14Non-Executive Independent Chairman recently bought US$84k worth of stockOn the 11th of May, Patrick LePore bought around 20k shares on-market at roughly US$4.18 per share. This was the largest purchase by an insider in the last 3 months. This was Patrick's only on-market trade for the last 12 months.
Price Target Changed • May 12Price target decreased to US$5.88Down from US$6.38, the current price target is an average from 5 analysts. New target price is 41% above last closing price of US$4.17. Stock is down 44% over the past year.
Reported Earnings • May 07Third quarter 2021 earnings released: US$0.18 loss per share (vs US$0.43 loss in 3Q 2020)The company reported a decent third quarter result with reduced losses and improved control over expenses, although revenues were weaker. Third quarter 2021 results: Revenue: US$112.4m (down 22% from 3Q 2020). Net loss: US$7.14m (loss narrowed 57% from 3Q 2020). Over the last 3 years on average, earnings per share has fallen by 1% per year but the company’s share price has fallen by 34% per year, which means it is performing significantly worse than earnings.
분석 기사 • Mar 18Is Lannett Company (NYSE:LCI) A Risky Investment?Warren Buffett famously said, 'Volatility is far from synonymous with risk.' When we think about how risky a company...
Is New 90 Day High Low • Feb 24New 90-day low: US$5.93The company is down 6.0% from its price of US$6.28 on 25 November 2020. The American market is up 5.0% over the last 90 days, indicating the company underperformed over that time. It also underperformed the Pharmaceuticals industry, which is up 8.0% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$25.11 per share.
Recent Insider Transactions • Feb 11Independent Director recently sold US$203k worth of stockOn the 8th of February, David Drabik sold around 33k shares on-market at roughly US$6.08 per share. This was the largest sale by an insider in the last 3 months. Insiders have been net sellers, collectively disposing of US$700k more than they bought in the last 12 months.
분석 기사 • Feb 11Independent Director David Drabik Just Sold A Bunch Of Shares In Lannett Company, Inc. (NYSE:LCI)We'd be surprised if Lannett Company, Inc. ( NYSE:LCI ) shareholders haven't noticed that the Independent Director...
Reported Earnings • Feb 05Second quarter 2021 earnings released: US$4.36 loss per share (vs US$0.13 profit in 2Q 2020)The company reported a poor second quarter result with weaker earnings, revenues and control over costs. Second quarter 2021 results: Revenue: US$133.9m (down 1.6% from 2Q 2020). Net loss: US$171.9m (down US$177.0m from profit in 2Q 2020). Over the last 3 years on average, earnings per share has fallen by 10% per year but the company’s share price has fallen by 30% per year, which means it is performing significantly worse than earnings.
Analyst Estimate Surprise Post Earnings • Feb 05Revenue and earnings beat expectationsRevenue exceeded analyst estimates by 3.0%. Earnings per share (EPS) also surpassed analyst estimates by 8,620%. Over the next year, revenue is forecast to grow 1.1%, compared to a 31% growth forecast for the Pharmaceuticals industry in the US.
Is New 90 Day High Low • Jan 26New 90-day high: US$7.93The company is up 19% from its price of US$6.67 on 27 October 2020. The American market is up 17% over the last 90 days, indicating the company outperformed over that time. It also outperformed the Pharmaceuticals industry, which is up 15% over the same period. According to the Simply Wall St valuation model, the estimated intrinsic value of the company is US$33.65 per share.
분석 기사 • Jan 15What Type Of Returns Would Lannett Company's(NYSE:LCI) Shareholders Have Earned If They Purchased Their SharesFive Years Ago?We're definitely into long term investing, but some companies are simply bad investments over any time frame. We really...
분석 기사 • Dec 11Is Lannett Company (NYSE:LCI) Using Too Much Debt?Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Reported Earnings • Nov 06First quarter 2021 earnings released: US$0.17 loss per shareThe company reported a decent first quarter result with reduced losses and improved control over expenses, although revenues were flat. First quarter 2021 results: Revenue: US$126.5m (flat on 1Q 2020). Net loss: US$6.50m (loss narrowed 47% from 1Q 2020). Over the last 3 years on average, earnings per share has fallen by 14% per year but the company’s share price has fallen by 37% per year, which means it is performing significantly worse than earnings.
Analyst Estimate Surprise Post Earnings • Nov 06Revenue and earnings miss expectationsRevenue missed analyst estimates by 1.9%. Earnings per share (EPS) were also behind analyst expectations. Over the next year, revenue is forecast to stay flat compared to a 31% growth forecast for the Pharmaceuticals industry in the US.
Price Target Changed • Oct 15Price target lowered to US$7.75Down from US$9.75, the current price target is an average from 5 analysts. The new target price is 16% above the current share price of US$6.66. As of last close, the stock is down 44% over the past year.